Rapid Decrease in Pruritus With Ruxolitinib Cream for Patients With Atopic Dermatitis: Pooled Results From TRuE-AD1 and TRuE-AD2

AAAAI February 26 - March 1, 2021, AAD VMX April 23-25, 2021; Virtual
Rapid, clinically meaningful, and continual improvement in itch observed with ruxolitinib cream for patients with atopic dermatitis.
Format: Microsoft PowerPoint (.ppt)
File Size: 453 KB
Released: June 18, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Incyte Corporation

Related Content

Expert faculty Benjamin Ungar, MD, discusses current and future treatment options for patients with prurigo nodularis (PN) from Clinical Care Options (CCO).

Benjamin Ungar, MD Released: September 16, 2022

Expert commentary reviews key concepts in the diagnosis and treatment of chronic spontaneous urticaria from Clinical Care Options (CCO).

Jonathan A. Bernstein, MD Released: September 15, 2022

Expert slides on new and emerging therapies, reducing healthcare disparities, and transitions of care in the management of moderate to severe atopic dermatitis

Robert Sidbury, MD, MPH Benjamin Ungar, MD Released: September 9, 2022

From Clinical Care Options (CCO) and Dr. Robert Sidbury, expert commentary on new data in atopic dermatitis evaluation and management.

Robert Sidbury, MD, MPH Released: June 30, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings